Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
196
resultados
Última actualización
23/10/2026 [06:53:00]
Resumen de: WO2025128082A1
A system and method for wireless transmission of glucose data. According to an embodiment of the present disclosure, there is provided a system, including: a glucose sensor; a beacon transmitter; and a processing circuit connected to the glucose sensor and the beacon transmitter, the processing circuit being configured to transmit a data packet, the data packet including measurement data including a measurement value, the measurement value being based on a glucose measurement.
Resumen de: AU2026238070A1
11201607_1 (GHMatters) P110945.AU Disclosed is an expression regulatory system for cell-specific transcription (expression) of a protein of interest, for example a cell cycle inducer that reactivates proliferation in adult or neonatal cardiomyocytes or insulin-producing beta cells. The expression regulatory system comprises a first nucleic acid that encodes a microRNA recognition element that specifically binds a target cell miR, and a translation suppressor protein; and a second nucleic acid that comprises a suppressor protein interaction motif that binds the translation suppressor protein, and a gene that encodes a protein of interest. When a cell of interest is co-transfected with the first and second nucleic acids of the system, the protein of interest expressed in a cell-specific fashion. ep e p
Resumen de: US20260314961A1
A blood glucose level measurement device includes a sensor portion that measures a blood glucose level of a user, a communication portion that transmits data representing the blood glucose level measured by the sensor portion to the outside, a flexible, sheet-shaped battery that supplies power to the sensor portion and the communication portion, a flexible, plate-shaped circuit portion that controls the operation of the communication portion, and an attachment portion configured to be attached to the body of the user. The battery has a peak current of 20 mA or more.
Resumen de: WO2026217569A1
Methods and compositions for treating Alzheimer's disease and related neurodegenerative conditions using intranasal nose-to-brain delivery of ST266, an amnion-derived cell secretome are described. ST266 is a multi-component, acellular biologic composition produced from amnion-derived multipotent progenitor (AMP) cells under cGMP conditions and comprising a plurality of anti-inflammatory, neuroprotective, anti-apoptotic, and regenerative cytokines and growth factors. When administered intranasally, ST266 bypasses the blood-brain barrier and simultaneously targets multiple pathological mechanisms underlying Alzheimer's disease, including neuroinflammation, insulin dysregulation, oxidative stress, neuronal damage, and synaptic dysfunction. The invention encompasses pharmaceutical compositions formulated for intranasal nose-to-brain delivery, methods of treating Alzheimer's disease by administering such compositions, and methods of reducing neuroinflammation and improving insulin regulation in the central nervous system. The non-invasive nature of intranasal delivery offers significant advantages in patient compliance and minimization of systemic side effects.
Resumen de: US20260315009A1
An autoregressive framework for synthetic data generation using an autoregressive generative model as an alternative to Generative Adversarial Networks (GAN). The autoregressive framework is applied to continuous glucose monitor data uses small real datasets to generate synthetic glycemic responses. The framework performs better than other systems because it works well with data constrained environments and can also evaluate contextual values in addition to past values.
Resumen de: US20260315755A1
Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspension of one or more ingredients. In embodiments of the present invention, amounts of the formulation and/or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.
Resumen de: WO2026214700A1
Provided in the present invention are a GLP-1/GLP-2 bispecific polypeptide and a fusion protein in which said polypeptide is fused to human IgG4-Fc. The GLP-1/GLP-2 bispecific polypeptide provided by the present invention can simultaneously activate GLP-1 and GLP-2 receptors, has a blood sugar control capability close to that of semaglutide, has a significant trophic effect on the small-intestine equivalent to that of teduglutide, and can markedly improve pathological features in mice with ulcerative colitis (UC).
Resumen de: US20260321378A1
0000 Provided are systems and methods using which users may learn and become familiar with the effects of various aspects of their lifestyle on their health, e.g., users may learn about how food and/or exercise affects their glucose level and other physiological parameters, as well as overall health. In some cases the user selects a program to try; in other cases, a computing environment embodying the system suggests programs to try, including on the basis of pattern recognition, i.e., by the computing environment determining how a user could improve a detected pattern in some way. In this way, users such as type II diabetics or even users who are only prediabetic or non-diabetic may learn healthy habits to benefit their health.
Resumen de: AU2026242095A1
Disclosed herein are an aqueous pharmaceutical formulation comprising cagrilintide and an aqueous formulation comprising semaglutide. The compositions of these two pharmaceutical formulations allow for their presentation in, and administration using, the dual-chamber medical device disclosed herein. Individuals with diseases, such as diabetes 5 and/or obesity and/or related co-morbidities, may benefit from the co-administration of semaglutide and cagrilintide, and/or of the two liquid pharmaceutical formulations disclosed herein, using the medical device disclosed herein. ep e p
Resumen de: US20260314958A1
0000 The present invention proposes a method of measuring the real-time level and degree of management of blood sugar based on an electrocardiogram. The method includes: obtaining an electrocardiogram signal measured for a user; estimating the user's blood sugar level by analyzing the electrocardiogram signal using a pre-trained first artificial intelligence, and determining whether the user has hyperglycemia or hypoglycemia by analyzing the electrocardiogram signal using an artificial intelligence; and determining whether the user needs guidance on blood sugar or diabetes based on the estimated blood sugar level and the result of the determination of whether the user has hyperglycemia or hypoglycemia. Through this, a user may check the user's immediate blood sugar level and how well the blood sugar is managed simply by measuring the electrocardiogram 10, and as a result, hyperglycemia and diabetes may be detected early or a complication attributable to hyperglycemia or diabetes may be prevented.
Resumen de: US20260315694A1
0000 Disclosed herein are systems and methods for the delivery of a co-formulation of insulin and a second drug, such as GLP-1, using an automated insulin delivery system. In a first embodiment, a dose of insulin is calculated by a medication delivery algorithm and a reduction factor is applied to account for the effect of second drug on the user's daily insulin requirement. In a second embodiment of the invention, a total amount of the second drug administered to the user during the past 24 hours is used to modify the correction factor and the insulin-to-carbohydrate ratio used by the medication delivery algorithm to cause a reduction in the insulin delivered to the user to account for the effect of the administration of the second drug portion of the co-formulation.
Resumen de: EP4821428A2
0001 Digital and graphical user interfaces for multi-analyte monitoring systems are provided. For example, disclosed herein are various embodiments of methods, systems, and interfaces for alarm interfaces, alarm settings interfaces, alarm unavailability interfaces and features, and sensor results interfaces. Various embodiments of interfaces relating to glucose and ketone sensing are disclosed herein.
Resumen de: WO2025122639A1
Certain aspects of the present disclosure relate to methods and systems for distinguishing between temporary compression of a sensor of a continuous analyte monitoring system and failure of the sensor, such as due to detachment of the sensor. In certain aspects, an apparatus includes an analyte sensor, a temperature sensor, a memory, and a processor communicatively coupled to the memory. The processor is configured to evaluate samples of an output of the analyte sensor and samples of an output of the temperature sensor with respect to a threshold condition. If the threshold condition is met, the processor is configured to generate a signal indicating failure of the analyte sensor.
Resumen de: US12758126B1
A wearable device is used to determine a glucose value for a portion of a user's body based on carbon dioxide emitted from the skin at the location of the wearable device. The device housing includes openings for carbon dioxide emitted by the user to enter and exit and may control accumulation of carbon dioxide within the housing using a valve, or allow carbon dioxide in the housing to reach an equilibrium value before determining a glucose value. Other sensors may be used to determine physiological or environmental factors, such as ambient carbon dioxide or increased respiration of the user, responsive to which a modifier may be applied to the determined glucose value.
Resumen de: US20260305988A1
0000 A system for displaying blood glucose information includes a blood glucose monitoring device configured to monitor blood glucose levels of a user, and a display. The system may also include one or more processors, and a non-transitory computer-readable medium containing instructions that, when executed by the one or more processors, cause the system to perform operations. The operations may include obtaining the blood glucose levels from the blood glucose monitoring device, where the blood glucose levels include at least a current blood glucose level and a historic blood glucose level. The operations may also include presenting the current blood glucose level at a first location on the display based on a first scale, and presenting the historic blood glucose level at a second location on the display based on a second scale different from the first scale.
Resumen de: WO2026211288A1
This liquid material for encapsulation at the time of intrauterine embryo transfer according to the present invention contains human serum albumin, glucose, alanyl-L-glutamine, hyaluronic acid, and two or more fatty acids. At least one unsaturated fatty acid selected from the group consisting of arachidonic acid, linoleic acid, linolenic acid, oleic acid, and palmitoleic acid and at least one saturated fatty acid selected from the group consisting of myristic acid, palmitic acid, and stearic acid are used as the two or more fatty acids.
Resumen de: WO2026212054A1
A method and smart glass for providing personalized information for health management are disclosed. The method comprises: acquiring an image through a camera; identifying at least one object included in the image acquired through the camera; acquiring sensing data related to blood glucose from an external electronic device; calculating at least one of a current blood glucose value and a predicted future blood glucose value based on the identified object and the sensing data; and displaying at least one of the current blood glucose value and the predicted future blood glucose value through a display.
Resumen de: US20260305975A1
0000 A non-invasive glycemic monitoring system uses a breath-sensing device to acquire repeated breath sessions from a user and to generate volatile organic compound information together with sample-quality and environmental information. A computing system receives a lab-derived A1C baseline for the user and uses the baseline with the breath-derived information to initialize and update a personalized model. Accepted breath sessions are stored in a rolling history and used to generate a projected A1C trend and a daily progress score or zone output representative of the user’s glycemic trajectory. In some embodiments, humidity, temperature, and sample-quality information are used to normalize breath-session data, and optional external inputs including finger-stick data, continuous glucose monitor data, or other external data are fused with the breath-derived information to refine personalization, anomaly handling, reporting, and confirmatory prompts.
Resumen de: WO2026213025A1
The present examples relate generally to apparatuses, systems, and methods for force reduction for medical device sensors. The apparatuses, systems, and methods may be directed to force reduction for a transcutaneous analyte sensor for insertion into a host. The medical device may comprise an on-skin wearable medical device. The on-skin wearable medical device may include a transcutaneous glucose sensor.
Resumen de: US20260308529A1
0000 Disclosed herein are compositions and methods for generating compositions comprising cell-based therapeutics useful for treating pancreatic disorders, including Type 1 diabetes.
Resumen de: WO2026212052A1
A method and an electronic device for monitoring a user's health status using a generative artificial intelligence model are provided. The method includes: acquiring user condition information including at least one of blood glucose, blood pressure, heart rate, ketone concentration, cholesterol, lactate, or insulin from an external electronic device; acquiring history information related to the user condition information; determining the user's health status by using the generative artificial intelligence model based on the user condition information and the history information; determining information or a service for the user based on the user's health status; and providing the information or the service.
Resumen de: US20260308530A1
0000 Disclosed herein are compositions and methods to differentiate pancreatic cells into functional insulin-producing CD133/Ki-67-positive activated islet proliferating cells (AIPCs) derived from isolated pancreatic islets and expand derived-AIPCs in in vitro cultures using a culture medium comprising an active agent. Also disclosed herein is the use of the AIPCs for implantation into a mammal for in vivo therapy, specifically for pancreatic disorders, including diabetes type I.
Resumen de: WO2026211868A1
The present invention relates to an agent for improving the characteristics of a peptide and a method for improving the characteristics of a peptide. The present invention also relates to an α-glucosidase having the activity of binding D-glucose to an N-protective amino acid. The present invention also relates to a method for producing an amino acid glycoside. TThe present invention also relates to a method for producing an amino acid glycoside. The agent and method of the present invention utilize a single amino acid glycoside, or a dipeptide or tripeptide containing one or more amino acid glycosides. The α-glucosidase of the present invention has: (1) an amino acid sequence of SEQ ID NO: 11; (2) an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in SEQ ID NO: 11; or (3) an amino acid sequence having at least 80% identity with the amino acid sequence of SEQ ID NO: 11. The α-glucosidase of the present invention has: (1) an amino acid sequence of SEQ ID NO: 14; (2) an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in SEQ ID NO: 14; or (3) an amino acid sequence having at least 80% identity with the amino acid sequence of SEQ ID NO: 14. A method for producing amino acid glycosides of the present invention includes a step for generating amino acid glycosides by reacting a carbohydrate hydrolase that acts on amino acids or amino acid derivatives and binds D-glucose with a par
Resumen de: WO2026212984A1
In some embodiments, a system for optimizing insulin bolus timing for a patient includes a continuous glucose monitoring (CGM) sensor worn by the patient, where the CGM sensor is operable to generate time-series glucose measurements. The system also includes one or more memories having executable instructions and one or more processors in data communication with the one or more memories. The one or more processors are configured to execute the executable instructions to perform one or more operations that include receiving the time-series glucose measurements and automatically determining a current need for an insulin bolus based on an evaluation of the time-series glucose measurements over a current period, where the current need corresponds to an affirmative determination or a negative determination. The one or more operations further include conditionally inviting the patient to initiate an application flow for automatically determining insulin bolus advice based on the current need.
Nº publicación: US20260309669A1 08/10/2026
Solicitante:
ABBOTT DIABETES CARE INC [US]
Abbott Diabetes Care Inc.
Resumen de: US20260309669A1
Creatinine levels may be monitored as a measure of kidney function. Conventionally, blood and/or urine tests are used for this purpose. Analyte sensors capable of monitoring creatinine in vivo may comprise: a sensor tail comprising at least a first working electrode, a creatinine-responsive active area disposed upon a surface of the first working electrode, a first membrane that is permeable to creatinine and overcoats the creatinine-responsive active area, and an oxygen scavenger located upon the sensor tail in proximity to the creatinine-responsive active area. The creatinine-responsive active area comprises a first electron transfer agent, a first polymer, and an enzyme system comprising multiple enzymes, particularly creatinine amidohydrolase, creatine amidinohydrolase, and sarcosine oxidase, that are capable of acting in concert to facilitate detection of creatinine. An oxidase enzyme may serve as the oxygen scavenger, particularly glucose oxidase when detecting creatinine in fluids also containing glucose.
BOPI
Sede Electrónica
